Artesunate alleviates the inflammatory response of ulcerative colitis by regulating the expression of miR-155

References

• Béres NJ, Szabó D, Kocsis D, Szűcs D, Kiss Z, Müller KE, Lendvai G, Kiss A, Arató A, Sziksz E, et al. 2016. Role of altered expression of miR-146a, miR-155, and miR-122 in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 22:327–335.
   PubMed Web of Science ®Google Scholar
• Castelli AA, Estrada JJ, Kaminski JP. 2018. Patient with ulcerative colitis and abdominal pain. JAMA Surg. 153:282–283.
   PubMed Web of Science ®Google Scholar
• Chen YX, Zhang XQ, Yu CG, Huang SL, Xie Y, Dou XT, Liu WJ, Zou XP. 2019. Artesunate exerts protective effects against ulcerative colitis via suppressing Toll‑like receptor 4 and its downstream nuclear factor‑κB signaling pathways. Mol Med Rep. 20:1321–1332.
   PubMed Web of Science ®Google Scholar
• Cooper HS, Murthy S, Shah R, Sedergran D. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Inves. 69:238–249.
   PubMed Web of Science ®Google Scholar
• da Silva BC, Lyra AC, Mendes CM, Ribeiro CP, Lisboa SR, de Souza MT, Portela RC, Santana GO. 2015. The demographic and clinical characteristics of ulcerative colitis in a northeast Brazilian population. Biomed Res Int. 2015:359130.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, et al. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 376:1647–1657.
   PubMed Web of Science ®Google Scholar
• Głąbska D, Guzek D, Zakrzewska P, Lech G. 2019. Intake of lutein and zeaxanthin as a possible factor influencing gastrointestinal symptoms in Caucasian individuals with ulcerative colitis in remission phase. JCM. 8:77–77.
   Google Scholar
• Gu P, Zhu L, Liu Y, Zhang L, Liu J, Shen H. 2017. Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF-kappaB pathway and apoptosis in mice. Int Immunopharmacol. 50:152–160.
   PubMed Web of Science ®Google Scholar
• Hou J, Hu X, Chen B, Chen X, Zhao L, Chen Z, Liu F, Liu Z. 2017. miR-155 targets Est-1 and induces ulcerative colitis via the IL-23/17/6-mediated Th17 pathway. Pathol Res Pract. 213:1289–1295.
   PubMed Web of Science ®Google Scholar
• Kalla R, Ventham N, Kennedy N, Quintana J, Nimmo E, Buck A, Satsangi J. 2015. MicroRNAs: new players in IBD. Gut. 64:504–513.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, Kim HJ, Kim WH, Kim JY, Chang DK. 2009. Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol. 24:667–671.
   PubMed Web of Science ®Google Scholar
• Kim JW, Hwang SW, Park SH, Song TJ, Kim MH, Lee HS, Ye BD, Yang DH, Kim KJ, Byeon JS, et al. 2017. Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol. 23:3505–3512.
   PubMed Web of Science ®Google Scholar
• Kunte R, Kunwar R. 2011. WHO Guidelines for the treatment of malaria. Med J Armed Forces India. 67:376–376.
   Google Scholar
• Li T, Chen H, Yang Z, Liu XG, Zhang LM, Wang H. 2013. Evaluation of the immunosuppressive activity of artesunate in vitro and in vivo. Int Immunopharmacol. 16:306–312.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang J, Guo H, Yang S, Fan W, Ye N, Tian Z, Yu T, Ai G, Shen Z, et al. 2018. Critical role of alternative M2 skewing in miR-155 deletion-mediated protection of colitis. Front Immunol. 9:904–915.
   PubMed Web of Science ®Google Scholar
• Liao Y, Lei J, Liu M, Lin W, Hong D, Tuo Y, Jiang MH, Xia H, Wang M, Huang W, et al. 2016. Mesenchymal stromal cells mitigate experimental colitis via insulin-like growth factor binding protein 7-mediated immunosuppression. Mol Ther. 24:1860–1872.
   PubMed Web of Science ®Google Scholar
• Li Y, Mu W, Xu B, Ren J, Wahafu T, Wuermanbieke S, Ma H, Gao H, Liu Y, Zhang K, et al. 2019. Artesunate, an anti-malaria agent, attenuates experimental osteoarthritis by inhibiting bone resorption and CD31hiEmcnhi vessel formation in subchondral bone. Front Pharmacol. 10:685.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 25:402–408.
   PubMed Web of Science ®Google Scholar
• Lu H, Wang B, Cui N, Zhang Y. 2018. Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS‑dependent p38 MAPK and protects against cerebral ischemia‑reperfusion injury. Molr Med Rep. 17:6639–6646.
   PubMed Web of Science ®Google Scholar
• Lv B, Liu Z, Wang S, Liu F, Yang X, Hou J, Hou Z, Chen B. 2014. MiR-29a promotes intestinal epithelial apoptosis in ulcerative colitis by down-regulating Mcl-1. Int J Clin Exp Pathol. 7:8542–8552.
   PubMed Web of Science ®Google Scholar
• Min M, Peng L, Yang Y, Guo M, Wang W, Sun G. 2014. MicroRNA-155 is involved in the pathogenesis of ulcerative colitis by targeting FOXO3a. Inflamm Bowel Dis. 20:652–659.
   PubMed Web of Science ®Google Scholar
• Nunes JJ, Pandey SK, Yadav A, Goel S, Ateeq B. 2017. Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens. Neoplasia. 19:333–345.
   PubMed Web of Science ®Google Scholar
• Seidelin JB, Nielsen OH. 2009. Epithelial apoptosis: cause or consequence of ulcerative colitis? Scand J Gastroenterol. 44:1429–1434.
   PubMed Web of Science ®Google Scholar
• Shanahan F. 1993. Pathogenesis of ulcerative colitis. The Lancet. 342:407–411.
   PubMed Web of Science ®Google Scholar
• Singh UP, Murphy AE, Enos RT, Shamran HA, Singh NP, Guan H, Hegde VL, Fan D, Price RL, Taub DD, et al. 2014. miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology. 143:478–489.
   PubMed Web of Science ®Google Scholar
• Tian T, Zhou Y, Feng X, Ye S, Wang H, Wu W, Tan W, Yu C, Hu J, Zheng R, et al. 2016. MicroRNA-16 is putatively involved in the NF-κB pathway regulation in ulcerative colitis through adenosine A2a receptor (A2aAR) mRNA targeting. Sci Rep. 6:30824.
   PubMed Web of Science ®Google Scholar
• Tolstanova G, Khomenko T, Deng X, Szabo S, Sandor Z. 2010. New molecular mechanisms of the unexpectedly complex role of VEGF in ulcerative colitis. Biochem Biophys Res Commun. 399:613–616.
   PubMed Web of Science ®Google Scholar
• Xu XM, Zhang HJ. 2016. miRNAs as new molecular insights into inflammatory bowel disease: crucial regulators in autoimmunity and inflammation. World J Gastroenterol. 22:2206–2218.
   PubMed Web of Science ®Google Scholar
• Xue M, Shi L, Wang W, Chen S, Wang L. 2018. An overview of molecular profiles in ulcerative colitis-related cancer. Inflamm Bowel Dis. 24:1883–1894.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ding J, Yang C, Gao Y, Li X, Chen X, Peng Y, Fang J, Xiao S. 2012. Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis. Curr Med Chem. 19:4541–4551.
   PubMed Web of Science ®Google Scholar
• Zeng XZ, Zhang YY, Yang Q, Wang S, Zou BH, Tan YH, Zou M, Liu SW, Li XJ. 2019. Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway. Acta Pharmacol Sin. 41:229–236.
   PubMed Web of Science ®Google Scholar
• Zhao K, Song Z. 1989. Distribution and excretion of artesunate in rats. Proc Chin Acad Med Sci Peking Union Med Coll. 4:186–188.
   PubMedGoogle Scholar
• Zhong W, Lu X, Shi H, Zhao G, Song Y, Wang Y, Zhang J, Jin Y, Wang S. 2017. Distinct microbial populations exist in the mucosa-associated microbiota of diarrhea predominant irritable bowel syndrome and ulcerative colitis. J Clin Gastroenterol. 53:660–672.
   Web of Science ®Google Scholar
• Zuo S, Li Q, Liu X, Feng H, Chen Y. 2016. The potential therapeutic effects of artesunate on stroke and other central nervous system diseases. Biomed Res Int. 2016:1489050.
   PubMed Web of Science ®Google Scholar